Iniectio CSF Cytostatica Polyquaternium, rhG,
Description:
depictio producti
CytostaticaPolyquaternium, rhG CSF Iniectio, for the patients of non-myeloablative malignancy with the treatment of antineoplastic, when may have clinic significance of febrile neutrophilic reduce myelosuppression, using this product to reduce the incidence rate of infection caused by febrile neutropenia. Iniectio CSF Cytostatica Polyquaternium, rhG, non usus ad arma sensisse eum in cellula hematopoietic caule cellam translationi periphericis parentis sanguis.
nomen medicamento
Nomen genericum. PEGylated recombinante Humanum Granulocito coloniam precursor Iniectio
Nomen anglicus. PEGylated recombinante Humanum Granulocito coloniam precursor Iniectio
Iniectio CSF Cytostatica Polyquaternium, rhG, Description
patet liquido
Iniectio CSF Cytostatica Polyquaternium, rhG,Indicia
1. Hoc est propter in curatio de cum aegris est non-myeloablative malignitatem antineoplásicos cum inhaero may have momenti neutrophilic redigendum myelosuppression lingua sed torpet, reducere incidentiae rate of usura is uber ut infectio per lingua sed torpet neutropenia fecit.
2. Hoc productum est non usus ad arma sensisse eum in cellula hematopoietic caule cellam translationi periphericis parentis sanguis.
Iniectio CSF Cytostatica Polyquaternium, rhG, Contraindication
Est quia prohibitus peg-allergic ad, rhG CSF, rhG CSF, et alia expressio E.coli preparations.The serosum vehentem cum aegris iecoris, renibus, cor, pulmonem Praesent sit debilitatum.
Iniectio CSF Cytostatica Polyquaternium, rhG, Product imaginibus
Iniectio Payment Terms and CSF-Lorem rhG Cytostatica Polyquaternium,
specification 3 mg/ml
packaging 1 bottle/box
Apparatum iniectio